P21 vs Selank.

P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF). It was designed by researchers at the New York State Institute for Basic Research to be an orally active, blood-brain-barrier-penetrant neurotrophic compound. It has been investigated in animal models of Alzheimer's disease, Down syndrome and other neurodegenerative and neurodevelopmental conditions. It is an early-stage research compound that has not been tested in humans.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, with the laboratory designation TP-7. It is a stabilized analog of tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G; the added Pro-Gly-Pro tail confers resistance to enzymatic degradation. It is studied primarily as an anxiolytic and nootropic agent and is most associated with Russian neuropharmacology research.

P21 is reported to act partly by inhibiting the leukemia inhibitory factor (LIF) signaling pathway and by increasing transcription of brain-derived neurotrophic factor (BDNF). Elevated BDNF is proposed to enhance neurogenesis and synaptic plasticity and to reduce the activity of GSK-3 beta, an enzyme that drives abnormal tau phosphorylation. Through this pathway it is hypothesized to have a disease-modifying effect on tau-related pathology. These mechanisms are drawn from cell-culture and rodent studies.

Selank's parent peptide tuftsin acts on immune cells, and Selank retains immunomodulatory activity while shifting toward neuromodulation. Proposed central mechanisms include modulation of monoamine systems (serotonin, dopamine, noradrenaline) and interaction with the GABAergic and enkephalin/opioid systems; Selank has been reported to inhibit enkephalin-degrading enzymes, prolonging the action of endogenous enkephalins. It has also been reported to influence expression of brain-derived neurotrophic factor (BDNF) and to alter cytokine balance (e.g., IL-6 and interferon-related signaling). These mechanisms are largely characterized in rodent and in vitro models rather than established in humans.

The evidence for P21 is entirely preclinical and comes largely from a single research group. In triple-transgenic Alzheimer's (3xTg-AD) mice, chronic oral P021 reduced tau hyperphosphorylation and rescued neurogenesis, synaptic markers and cognition (Kazim et al., Neurobiology of Disease 2014). A later study reported that early P021 treatment prevented dendritic and synaptic deficits and cognitive impairment in the same model (Baazaoui and Iqbal, Alzheimer's Research and Therapy 2017). Subsequent work from the same laboratory extended the approach to treatment begun in early postnatal development, again in a transgenic rodent model, and reported prevention of Alzheimer-like behavior and synaptic dysfunction (Journal of Alzheimer's Disease, 2021). A later review by the same investigators frames the compound as a therapeutic opportunity to be tested rather than an established treatment (Biomolecules, 2022). The design of this body of work sets clear limits on what it can support. These are rodent experiments in genetically engineered models that reproduce selected features of human Alzheimer's pathology and that have a long record of poor translation to the clinic. They were conducted by the originating institution rather than by independent replicating laboratories, and the published reports are academic studies, not blinded, multi-site, pre-registered confirmatory trials. The outcomes are surrogate measures: phosphorylated tau, synaptic protein density, neurogenesis markers, and rodent behavioral tasks. None is a clinical endpoint, and treatment durations span weeks to months of animal life rather than years of human disease. What is unknown is more substantial than what has been shown. No human clinical trial of P21 has been completed or registered. There is therefore no Phase 1 dataset, no human pharmacokinetic or bioavailability profile despite the oral-activity claim, no characterized exposure range, and no published formal toxicology package. The contrast with the class it is compared against is stark: approved central nervous system drugs for Alzheimer's disease have moved through sequential Phase 1, 2 and 3 programs enrolling thousands of participants with adjudicated cognitive and functional endpoints, and even candidates that failed later usually established a human tolerability and exposure baseline in Phase 1. P21 has not reached that first step. Positive rodent findings do not establish efficacy or safety in people.

The great majority of Selank evidence is preclinical (rodent and in vitro), covering anxiolytic-like behavior, stress models, immune/cytokine modulation, and tissue effects under chronic stress (e.g., Bull Exp Biol Med studies on rat intestine and liver under restraint/foot-shock stress, and a cytokine study under 'social' stress). Human clinical data are limited and come almost entirely from Russian-language trials and registry approval rather than large, independently replicated, placebo-controlled studies indexed in Western literature; reported uses include generalized anxiety disorder and asthenic/neurasthenic conditions. A frequently cited molecular review (Protein and Peptide Letters, 2018, PMID 30255741) summarizes the proposed biology. Overall, robust, independently replicated human efficacy data are thin, and mechanistic plausibility should not be read as proven clinical benefit.

There are no human safety data for P21; all safety information comes from short- to medium-term rodent studies, where it was reported to be tolerated. Long-term effects, appropriate exposure and human toxicology are unknown. No published Phase 1 study has characterized adverse events, dose-limiting toxicity, immunogenicity, or interactions with other medicines in people, and there is no public repeat-dose toxicology, reproductive toxicity, or carcinogenicity dataset of the kind regulators expect before first-in-human testing. Because the proposed mechanism involves raising brain-derived neurotrophic factor and modulating leukemia inhibitory factor signaling, pathways that influence cell growth, survival and inflammation in many tissues, chronic systemic effects cannot be excluded on the basis of rodent behavioral studies alone. Material sold as a research chemical is not quality-controlled for purity or identity. Products of this type are produced outside pharmaceutical good manufacturing practice oversight, are not reliably tested batch by batch for peptide content, related-substance impurities, endotoxin, or residual synthesis reagents, and are labeled for laboratory use rather than administration. A purchaser has no practical way to verify what a vial contains, and the sterility of any reconstituted preparation is unverified. The absence of documented adverse events should not be read as evidence of safety. It reflects the absence of any human exposure under systematic observation, not a record of uneventful use: with no clinical monitoring, no adverse-event reporting channel and no registry, harms would simply go unrecorded. It is not a medicine and is not intended for human use.

Published reports, mostly from the developing Russian groups, describe Selank as generally well tolerated with a notably low sedation, dependence, and withdrawal profile compared with benzodiazepines, but rigorous long-term and large-sample safety data from independent groups are lacking. Because much of the safety record comes from the originating institutions and small studies, the true adverse-event and long-term safety profile in humans is not well established. As a peptide typically administered intranasally in research, purity, contamination, and product-quality concerns apply to non-pharmaceutical material. It has not undergone the comprehensive safety review required for major regulatory approval outside its country of origin.

P21 is not approved by the FDA or any other regulatory authority and has no approved medical use. It exists only as a preclinical research compound. This content is educational only and contains no dosing guidance.

Selank is reported to have been registered/approved in Russia (around 2009) for anxiety and asthenic conditions, marketed as an intranasal preparation. It is not approved by the US FDA and is not an approved drug in the EU; outside Russia it is effectively investigational and is widely sold as a research-use-only / not-for-human-consumption chemical. It is not a controlled substance and is not a standard WADA-prohibited agent, but its unapproved status means quality and legality vary by jurisdiction.